Kyverna Therapeutics To Present Full One-Year Data Set From KYSA-8, Registrational Trial Of Miv-Cel In Patients With Stiff Person Syndrome, At MS Toronto 2026, Joint ACTRIMS-ECTRIMS Meeting
Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies Deep B-cell depletion demonstrated
A company is showing that their new medicine helped sick people feel better for a whole year. When a medicine works this well in tests, it means the company might be able to sell it soon.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.